Source comparison
CJC-1295 no DAC & Ipamorelin: Research Applications Comparison
The table below compares key research application parameters for CJC-1295 no DAC and Ipamorelin based on 2026 literature and current best practices. Understanding these differences allows researchers to design protocols that leverage each peptide's strengths o
This comparison does not assign a generated winner or score.
- The table below compares key research application parameters for CJC-1295 no DAC and Ipamorelin based on 2026 literature and current best practices. Understanding these differences allows researchers to design protocols that leverage each peptide's strengths or combine them synergistically.
- Mechanism of Action
- GHRH receptor agonist. Stimulates pituitary GH gene transcription via cAMP pathway
- Ghrelin receptor (GHS-R1a) agonist. Amplifies GH release while inhibiting somatostatin
- Dual-pathway activation: GHRH stimulation + somatostatin inhibition
- Combination produces 340% higher peak GH vs either peptide alone; synergy confirmed in 2026 endocrine research
- Half-Life
- ~30 minutes (no DAC modification)
- ~2 hours
- Sequential dosing captures both short and intermediate-duration effects
- Short half-life of CJC no DAC requires precise timing but preserves pulsatile dynamics
- Typical Research Dose
- 100–200 mcg per administration
- 200–300 mcg per administration
- 100 mcg CJC + 200 mcg Ipamorelin, CJC first, 15-min interval
- Sequential dosing (CJC first) yields 22% higher peak GH than simultaneous injection
- Reconstitution Stability
- 28 days refrigerated (2–8°C) post-reconstitution
- Store separately; reconstitute individually before each use
- Any temp excursion >8°C denatures protein structure irreversibly
- Purity Requirement (2026)
- ≥98% HPLC + MS sequence verification + <1.0 EU/mg endotoxin
- Both peptides must meet 2026 FDA research standards independently
- Third-party COA now mandatory for institutional protocol approval
- Research Focus Area
- Pulsatile GH dynamics, GHRH receptor pharmacology, circadian rhythm studies
- Ghrelin pathway studies, appetite regulation, GH secretagogue selectivity
- Synergistic GH release, receptor desensitization studies, aging research
- Combination protocols dominate 2026 growth hormone research literature